Consort Medical plc (LON:CSRT) insider Paul Hayes acquired 14 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was bought at an average price of GBX 1,088 ($14.05) per share, with a total value of £152.32 ($196.72).

Paul Hayes also recently made the following trade(s):

  • On Monday, August 7th, Paul Hayes acquired 13 shares of Consort Medical plc stock. The stock was bought at an average price of GBX 1,100 ($14.21) per share, with a total value of £143 ($184.68).
  • On Tuesday, June 20th, Paul Hayes acquired 4,000 shares of Consort Medical plc stock. The stock was bought at an average price of GBX 1,094 ($14.13) per share, with a total value of £43,760 ($56,515.56).

Shares of Consort Medical plc (LON CSRT) opened at 1061.00 on Wednesday. The stock has a 50 day moving average of GBX 1,084.32 and a 200-day moving average of GBX 1,048.90. Consort Medical plc has a one year low of GBX 960.00 and a one year high of GBX 1,180.00. The stock’s market capitalization is GBX 518.97 million.

The firm also recently declared a dividend, which will be paid on Friday, October 27th. Stockholders of record on Thursday, September 21st will be issued a GBX 13.21 ($0.17) dividend. The ex-dividend date is Thursday, September 21st. This is a positive change from Consort Medical plc’s previous dividend of $7.09. This represents a dividend yield of 1.3%.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/09/12/paul-hayes-purchases-14-shares-of-consort-medical-plc-csrt-stock.html.

Several equities analysts have issued reports on CSRT shares. Investec restated a “buy” rating and issued a GBX 1,165 ($15.05) price objective on shares of Consort Medical plc in a research note on Thursday, June 15th. N+1 Singer restated a “buy” rating and issued a GBX 1,125 ($14.53) price objective on shares of Consort Medical plc in a research note on Thursday, June 15th. Shore Capital restated a “buy” rating on shares of Consort Medical plc in a research note on Thursday, June 15th. Panmure Gordon restated a “buy” rating and issued a GBX 1,145 ($14.79) price objective on shares of Consort Medical plc in a research note on Thursday, June 15th. Finally, Numis Securities Ltd restated a “hold” rating and issued a GBX 1,084 ($14.00) price objective on shares of Consort Medical plc in a research note on Thursday, June 15th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Consort Medical plc presently has an average rating of “Buy” and an average target price of GBX 1,153.17 ($14.89).

About Consort Medical plc

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Receive News & Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related companies with MarketBeat.com's FREE daily email newsletter.